StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Castle Biosciences's EV/EBITDA was 111.3× on Jan 30, 2026, against 42.0× a year earlier. Over the last 3 years it ranged from 6.0× to 113.4×, with a median of 46.5×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 2026111.3×+1.8
2025Dec 31, 2025109.5×+71.1
2024Dec 31, 202438.3×−61.8
2020Oct 30, 2020100.2×+45.6
2019Dec 31, 201954.6×–

More Castle Biosciences figures

See a number that looks wrong?